中信建投：发行不超200亿元永续次级公司债券获批 7月2日晚，中信建投（601066）发布公告称，公司收到中国证监会批复，同意公司向专业投资者公开发 行面值总额不超过200亿元永续次级公司债券注册申请。该批复自同意注册之日起24个月内有效，公司 在注册有效期内可以分期发行永续次级公司债券。 蓝思科技：获中信银行9亿元贷款承诺用于股票回购 7月2日晚，蓝思科技（300433）发布公告称，公司收到中信银行股份有限公司长沙分行出具的《贷款承 诺函》，将为其提供不超过9亿元的贷款，专项用于支持公司回购股票。 资料显示，蓝思科技成立于2006年12月，主营业务是智能终端全产业链一站式精密制造解决方案。 所属行业：电子–消费电子–消费电子零部件及组装 华仁药业：全资子公司布美他尼原料药获批上市 7月2日晚，华仁药业（300110）发布公告称，公司收到国家药品监督管理局核准签发的布美他尼原料药 《化学原料药上市申请批准通知书》。布美他尼适用于治疗严重心力衰竭、高血压急症及严重钠潴留 等，其利尿作用强，对肾功能影响小。 资料显示，华仁药业成立于1998年5月，是一家集研发、生产、销售为一体的,以肾科、呼吸科、精麻 科、治疗性 ...

智通财经7月2日电，复星医药(600196.SH)公告称，控股子公司上海复宏汉霖生物医药有限公司收到比 利时联邦药品和保健产品管理局颁发的《药品GMP证书》，认证产品为帕妥珠单抗注射液（HLX11） 和地舒单抗注射液（HLX14）。本次GMP认证所涉生产设施累计投入约为人民币23,582万元。帕妥珠单 抗注射液2024年全球销售额约为33.22亿美元，地舒单抗注射液2024年全球销售额约为74.62亿美元。本 次GMP认证不会对公司现阶段业绩产生重大影响，药品具体销售情况可能受到多种因素影响，具有较 大不确定性。 复星医药：控股子公司获欧盟药品GMP证书 ...

Core Viewpoint - The approval of the two biosimilar drugs, Deshu Single Antibody Injection, by the Macau Drug Regulatory Authority marks a significant milestone for the company, as it is the first major oncology drug from its collaborative products to gain market entry in the Hong Kong and Macau regions [1][2]. Group 1: Product Details - The two approved products are Deshu Single Antibody Injection in 60mg (brand name: Boyoubai) and 120mg (brand name: Boluoga), which are biosimilars of Prolia and Xgeva, respectively [1][2]. - Boyoubai is indicated for osteoporosis in postmenopausal women at high risk of fractures, while Boluoga is used for treating giant cell tumors of bone that cannot be surgically removed or where surgery may lead to severe functional impairment [2]. Group 2: Market Potential - The Chinese market for Deshu Single Antibody is projected to reach 3.741 billion yuan by 2025 and may exceed 10 billion yuan by 2030, driven by an aging population and increasing treatment rates [3]. - In Macau, the population aged 65 and above accounted for 13.66% in 2023, indicating a significant demand for treatments related to osteoporosis and cancer [3]. Group 3: International Strategy - The company has adopted a "global selection, global coverage" strategy, focusing on high-growth emerging markets and the EU, leveraging cost-effective high-end biosimilars [4]. - The establishment of local teams in various countries aims to enhance market responsiveness and competitiveness, facilitating the introduction of products into the European and American markets [4]. - The approval of Deshu Single Antibody in Macau, along with the existing product "Kuyang Capsule" in Hong Kong, enhances the company's market presence in the Guangdong-Hong Kong-Macau Greater Bay Area [4].